113. Muscular dystrophy Clinical trials / Disease details
Clinical trials : 646 / Drugs : 471 - (DrugBank : 105) / Drug target genes : 59 - Drug target pathways : 170
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05338099 (ClinicalTrials.gov) | January 18, 2022 | 6/1/2022 | Determine the Safety and Dose of EN001 in Patients With Duchenne Muscular Dystrophy(DMD) | Open-label, Dose-escalation, Phase 1 Clinical Trial to Determine the Safety and Dose of EN001 in Patients With Duchenne Muscular Dystrophy(DMD) | Duchenne Muscular Dystrophy | Drug: EN001 | ENCell | NULL | Completed | 2 Years | 18 Years | Male | 7 | Phase 1 | Korea, Republic of |